← Search another drug
PatientPulse · by PatientPartner
Yescarta axicabtagene ciloleucel
High confidence
~56 public patient conversations, blogs, forums, and editorial pages referenced
Executive intelligence
The signal that moves starts & adherence
55%Positive sentiment in discussion
9,420FDA adverse-event reports
97%Flagged serious
39%Reports name female patients
The single biggest commercial lever is the pre-infusion anxiety window: patients who find a peer survivor before leukapheresis are far more likely to stay the course through CRS and ICANS fear.
- Patients frame Yescarta overwhelmingly as a last-resort miracle, with remission narratives dominating sentiment despite near-universal reports of serious acute toxicity including CRS, ICANS, and profound fatigue.
- CRS and neurologic side effects (brain fog, word-finding difficulty, confusion) are the dominant lived-experience fears, yet patients who received early peer education report feeling less blindsided and more resilient through the acute phase.
- Cost and insurance navigation represent a silent adherence risk: the list price exceeding $500K, prior-authorization delays, and post-infusion monitoring costs generate acute anxiety that can stall referral and timely cell collection.
- Emerging long-term neurotoxicity signals, including caregiver-reported dementia-like decline years post-infusion, represent an underexplored unmet need that patients are beginning to surface in forums and patient advocacy communities.